A Phase 3 interventional study of RG1068 (Synthetic Human Secretin) in Autism, sponsored by Repligen Corporation. Completed at 15 sites in United States. Open to participants aged 32 Months to 59 Months. Per ClinicalTrials.gov, last updated 2005-08-05.
Sponsored by Repligen Corporation · Phase 3, Interventional, and Treatment
The purpose of the study is to determine whether multiple doses of secretin are safe and effective in the treatment of children with autism.
1,344 studies on the registry are indexed under Autistic Disorder; 334 are open to participants now.
Browse Autistic Disorder studies →Repligen Corporation is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Autism
This study is completed, as verified in Aug 2005. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Repligen Corporation